CSF kynurenic acid and suicide risk in schizophrenia spectrum psychosis

Psychiatry Research

Volumn 205, Issue 1-2, 2013, Pages 165-167

  Carlborg, Andreas ^a   Jokinen, Jussi ^a   Jönsson, Erik G ^a   Erhardt, Sophie ^b   Nordström, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CSF KYNA; Schizophrenia; Suicide

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; KYNURENIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KYNURENIC ACID; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDE; SUICIDE, ATTEMPTED; YOUNG ADULT;

EID: 84872608295     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.08.021     Document Type: Article

References (12)

1. Åsberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Annals of the New York Academy of Sciences 1997, 836:158-181.
2. Carlborg A., Winnerbäck K., Jönsson E.G., Jokinen J., Nordström P. Suicide in schizophrenia. Expert Review of Neurotherapeutics 2010, 10:1153-1164.
3. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. Journal of Neuroscience 2001, 21:7463-7473.
4. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
5. Kessler M., Baudry M., Lynch G. Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites. Brain Research 1989, 489:377-382.
6. Lindqvist D., Janelidze S., Erhardt S., Träskman-Bendz L., Engström G., Brundin L. CSF biomarkers in suicide attempters-a principal component analysis. Acta Psychiatrica Scandinavica 2011, 124:52-61.
7. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindström L.H., Nordin C., Karanti A., Persson P., Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research 2005, 80:315-322.
8. Nilsson L.K., Nordin C., Jönsson E.G., Skogh E.G., Erhardt S. Cerebrospinal fluid kynurenic acid in male patients with schizophrenia-correlation with monoamine metabolites. Acta Neuropsychiatrica 2007, 19:45-52.
9. Sathyasaikumar K.V., Stachowski E.K., Wonodi I., Roberts R.C., Rassoulpour A., McMahon R.P., Schwarcz R. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophrenia Bulletin 2011, 37:1147-1156.
10. Sedvall G.C., Wode-Helgodt B. Abberant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Archives of General Psychiatry 1980, 37:1113-1116.
11. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., Mann J.J., Postolache T.T. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain, Behavior, and Immunity 2011, 25:1272-1278.
12. Vares M., Ekholm A., Sedvall G.C., Hall H., Jönsson E.G. Characterisation of patients with schizophrenia and related psychosis: evaluation of different diagnostic procedures. Psychopathology 2006, 39:286-295.